Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Present at Investor Conferences in November

BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
November 07, 2018 07:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage...
October 31, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018

BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
October 25, 2018 08:16 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors

BOSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
October 02, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
September 25, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Present at Investor Conferences in October

BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
September 14, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018

BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
September 10, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors

BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
September 04, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy

BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
August 30, 2018 08:00 ET | Source: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

BOSTON, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...